The largest holder of Bristol-Myers Squibb stock is Vanguard Capital Management LLC, with 133.3 million shares (6.53% of the company), worth about $8.91 billion as of September 25, 2026. The 10 largest holders together own 35.5%.
In Q2 2026, 2,647 institutional holdings reports listed 1.86 billion shares worth $108.00 billion, up 14.8% in shares from Q1 2026.
Insiders reported 58 transactions in the last two years: 7 sales worth $5.00 million and 4 purchases. The newest one on file is from September 9, 2026 (Massacesi Cristian, Officer).
Major holders as of September 25, 2026; quarterly totals from institutional holdings reports (latest Q2 2026); insider transactions on file through September 9, 2026.

2026Q2
| Holder | Shares | % of company | Value |
|---|---|---|---|
| Vanguard Capital Management LLC | 133.3 million | 6.53% | $8.9B |
| BlackRock Advisors LLC | 129.2 million | 6.32% | $8.6B |
| State Street Corporation | 102.4 million | 5.01% | $6.8B |
| JPMorgan Investment Management, Inc. | 71.7 million | 3.51% | $4.8B |
| Charles Schwab Investment Management, Inc. | 67.6 million | 3.31% | $4.5B |
| Geode Capital Management LLC | 56.4 million | 2.76% | $3.8B |
| Vanguard Portfolio Management LLC | 46.9 million | 2.29% | $3.1B |
| BlackRock Life Ltd. | 46.2 million | 2.26% | $3.1B |
| Norges Bank (13F) | 36.9 million | 1.80% | $2.5B |
| Merrill Lynch International | 34.1 million | 1.67% | $2.3B |
As of September 25, 2026.
| Quarter | Reports | Shares | Value |
|---|---|---|---|
| Q2 2026 | 2,647 | 1.86 billion | $108.0B |
| Q1 2026 | 2,671 | 1.62 billion | $98.1B |
| Q4 2025 | 2,576 | 1.65 billion | $88.8B |
| Q3 2025 | 2,415 | 1.67 billion | $75.5B |
| Q2 2025 | 2,429 | 1.66 billion | $76.9B |
| Q1 2025 | 2,610 | 1.64 billion | $99.7B |
| Q4 2024 | 2,618 | 1.60 billion | $90.5B |
| Q3 2024 | 2,395 | 1.64 billion | $84.5B |
Shares and value held by institutions that file quarterly holdings reports (options not included).
| Insider | Date | Title | Transaction | Value |
|---|---|---|---|---|
| Massacesi Cristian | Sep 9, 2026 | Officer | Sale at price 64.57 per share. | $403,498 |
| Short Bartie Wendy | Sep 1, 2026 | Officer | Conversion of Exercise of derivative security at price 66.92 per share. | $82,713 |
| Holzer Phil M | Aug 25, 2026 | Officer | Sale at price 67.50 per share. | $33,750 |
| Massacesi Cristian | Jul 31, 2026 | Officer | -- | – |
| Gallman Cari | Jul 31, 2026 | General Counsel | -- | – |
| Haller Julia A | Jun 15, 2026 | Director | Conversion of Exercise of derivative security at price 53.76 per share. | $1.1M |
| Short Bartie Wendy | Jun 3, 2026 | Officer | -- | – |
| Lenkowsky Adam | May 1, 2026 | Officer | -- | – |
| Elkins David Vincent | Apr 1, 2026 | Chief Financial Officer | Sale at price 61.60 - 62.05 per share. | $1.9M |
| Shanahan Karin | Apr 1, 2026 | Officer | -- | – |
| Short Bartie Wendy | Mar 10, 2026 | Officer | -- | – |
| Lenkowsky Adam | Mar 10, 2026 | Officer | -- | – |
Newest 12 of 58 insider transactions in the last two years.
Vanguard Capital Management LLC, with 6.53% of the company (as of September 25, 2026). Next: BlackRock Advisors LLC (6.32%) and State Street Corporation (5.01%).
2,647 institutional holdings reports listed Bristol-Myers Squibb shares in Q2 2026, 1.86 billion shares in all worth $108.00 billion.
In the last two years insiders reported 7 sales and 4 purchases (58 transactions in all); the newest on file is from September 9, 2026.